When the Supreme Court issued its order on Thursday, the press didn’t report on a legal procedure. They reported on a political fantasy.
Across the front pages – from national outlets to the Alabama Political Reporter – the verdict was unanimous: The court had “preserved” access to the abortion pill mifepristone. It was a clean, comforting narrative for a polarized public. It was also a legal fabrication.
The Supreme Court didn’t “preserve” anything. In Louisiana v. FDA, the justices didn’t vote to protect a drug or endorse the FDA’s regulatory record. They issued an emergency stay to maintain the status quo while litigation continues in the lower courts. This wasn’t a victory for reproductive rights or a defeat for the states. It was a procedural necessity to prevent a single lower court from upending national pharmaceutical rules before the merits of the case could be fully argued.
The headlines suggest a moral referendum, but the 7-2 order was unsigned and lacked a majority opinion for a reason: It was a technical intervention. By staying the Fifth Circuit’s injunction, the court signaled that a nationwide rollback of FDA rules is a bridge too far for the “emergency docket” when the jurisdictional foundation is still being litigated.
Join the conversation as a VIP Member